Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Trop Med Hyg. 1993 Nov;49(5):641-4.

A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans.

Author information

1
Departement de Maladies Infectieuses, Parasitaires, Tropicales et Sante Publique, Hopital de la Pitie-Salpetriere, Paris, France.

Abstract

In an open study, we compared the efficacy of single doses of oral ivermectin (12 mg) and oral albendazole (400 mg) for the treatment of cutaneous larva migrans. Twenty-one patients were randomly assigned to receive ivermectin (n = 10) or albendazole (n = 11). All patients who received ivermectin responded and none relapsed (cure rate = 100%). All but one patient in the group receiving albendazole responded, but five relapsed after a mean of 11 days (cure rate = 46%; P = 0.017). No major adverse effects were observed. We conclude that a single 12-mg dose of ivermectin is more effective than a single 400-mg dose of albendazole for the treatment of cutaneous larva migrans.

PMID:
8250105
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ingenta plc
    Loading ...
    Support Center